MCC 19487 A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma

Grant

Total Award Amount

  • 19201.00
  • Direct Costs

  • 14770.00
  • Sponsor Award Id

  • MCC 19487
  • Contributor

  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Jamie Aye   Investigator  
  • Kimberly Whelan M.D.   Principal Investigator